CervoMed Inc. (NASDAQ:CRVO – Free Report) – Research analysts at Chardan Capital issued their FY2024 earnings per share estimates for CervoMed in a research note issued on Wednesday, September 18th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($1.34) per share for the year. Chardan Capital currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.49) per share. Chardan Capital also issued estimates for CervoMed’s FY2025 earnings at ($1.26) EPS.
CervoMed (NASDAQ:CRVO – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $3.29 million during the quarter, compared to analysts’ expectations of $3.48 million. CervoMed had a negative return on equity of 27.91% and a negative net margin of 52.24%.
Read Our Latest Stock Analysis on CervoMed
CervoMed Price Performance
Shares of CRVO opened at $15.60 on Monday. CervoMed has a twelve month low of $4.28 and a twelve month high of $26.38. The firm has a 50 day moving average of $15.53 and a 200 day moving average of $18.98.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Crown Advisors Management Inc. purchased a new stake in shares of CervoMed during the 1st quarter valued at about $2,330,000. Ikarian Capital LLC bought a new position in CervoMed in the first quarter worth approximately $5,530,000. RA Capital Management L.P. bought a new position in CervoMed in the first quarter worth approximately $20,075,000. Bank of New York Mellon Corp purchased a new position in shares of CervoMed during the 2nd quarter worth $236,000. Finally, Rhumbline Advisers bought a new stake in shares of CervoMed during the 2nd quarter valued at $96,000. Institutional investors own 25.15% of the company’s stock.
CervoMed Company Profile
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Further Reading
- Five stocks we like better than CervoMed
- How to Use the MarketBeat Stock Screener
- The Average 401k Balance by Age Explained
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Investing in Travel Stocks Benefits
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.